NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financi...(ities 4480 5693 ...),Health

Date:5/18/2009

ities 4,480 5,693 Capital lease obligation - non-current 7 - Equipment loan - non-current 470 372 Deferred revenue - non-current 1,667 1,392 Total liabilities 6,624 7,457 Commitments and Contingencies Stockholders' Equity: Common stock, $0.01 par value; 65,000 and 65,000 shares authorized at December 31, 2008 and March 31, 2009, respectively; 21,471 and 21,662 shares issued and outstanding at December 31, 2008 and March 31, 2009, respectively 215 217 Additional paid-in capital 33,718 34,199 Accumulated other comprehensive income (loss) - (8) Accumulated deficit during development stage (26,588) (26,907) Total stockholders' equity 7,345 7,501 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $13,969 $14,958

                              NOVABAY PHARMACEUTICALS, INC
                         (formerly NovaCal Pharmaceuticals Inc.)
                             (a developmental stage company)

                          CONSOLIDATED STATEMENTS OF OPERATIONS
                           (in thousands, except per share data)

                                                                  Cumulative
                                                                    Period
                                                                     from
                                                                    July 1,
                                                                     2002
                                                                   (date of
                                                                  
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related medicine news :

1. NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Societys Highest Award
2. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
3. NovaBay announces third quarter 2007 financial results
4. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
8. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements